Schroeck, Florian R. http://orcid.org/0000-0002-1860-2611
Sirovich, Brenda
Seigne, John D.
Robertson, Douglas J.
Goodney, Philip P.
Funding for this research was provided by:
U.S. Department of Veterans Affairs (VISN1 Career Development Award)
American Cancer Society (IRG-82-003-30)
Conquer Cancer Foundation (Career Development Award)
U.S. Food and Drug Administration (U01FD005478-01)
Article History
Received: 16 January 2017
Accepted: 31 August 2017
First Online: 6 September 2017
Ethics approval and consent to participate
: The study was approved by the Dartmouth Committee for the Protection of Human Subjects (#28417) and by the Veteran’s Institutional Review Board of Northern New England (#897920-1). The study has a waiver of informed consent and is compliant with the Health Insurance Portability and Accountability Act.
: Not applicable.
: Florian R. Schroeck is Site PI (without any compensation) for the Phase III Trial of Vicinium (Viventia Biotech) and has received research funding from the U.S. Department of Veterans Affairs, Conquer Cancer Foundation, and American Cancer Society<b><i>.</i></b>John D. Seigne is an owner of 100 shares of common stock of Johnson & Johnson. The remaining authors declare that they have no relevant financial interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.